The Hetero Ring Contains Plural Ring Nitrogens Patents (Class 514/225.8)
-
Patent number: 10869908Abstract: Methods of inducing cell death by hyperactivation of motility networks are provided.Type: GrantFiled: February 24, 2017Date of Patent: December 22, 2020Assignee: The Johns Hopkins UniversityInventors: Peter Devreotes, Huaqing Cai, Marc Edwards, Jun Liu, Michele Vitolo, Thomas Lampert, Yu Long, Alexandra Debonnes
-
Patent number: 10597378Abstract: Disclosed are compounds of formula (I) below or pharmaceutically acceptable salts thereof: in which each of variables R1-R6, L, m, and n is defined herein. Also disclosed are a method for treating an opioid receptor-associated condition with a compound of formula (I) and a pharmaceutical composition containing same.Type: GrantFiled: September 8, 2017Date of Patent: March 24, 2020Assignee: National Health Research InstitutesInventors: Shau-Hua Ueng, Shiu-Hwa Yeh, Po-Kuan Chao, Chuan Shih
-
Patent number: 10555962Abstract: The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.Type: GrantFiled: October 20, 2014Date of Patent: February 11, 2020Assignee: Lunan Pharmaceutical Group CorporationInventors: Zhiquan Zhao, Jingchun Yao, Xin Li, Yongxia Guan, Guangyan Li
-
Patent number: 10046052Abstract: Methods and dosage formulations for the safe treatment of cold, cough, flu, and sinus symptoms in children and adolescents by age and nature of symptoms, and adults and the elderly by age, nature of symptoms, and concomitant patient medical conditions. The method of the present invention comprises the formulation of a cold medication which consists essentially of combinations of a nonsedating or minimally sedating antihistamines with pain relievers and the expectorant, guaifenesin.Type: GrantFiled: May 16, 2011Date of Patent: August 14, 2018Inventor: Bernard Silverman
-
Patent number: 9957494Abstract: In some embodiments, the present invention provides method of identifying compounds that bind to phosphoinositol 4-phosphate adaptor protein-2 (FAPP2), including the steps of computationally identifying a compound that binds to FAPP2 using the atomic coordinates of at least the amino acids which make up the substrate binding pocket of FAPP2. Also provided are methods of designing, selecting and/or optimizing a compound that binds to FAPP2.Type: GrantFiled: July 23, 2015Date of Patent: May 1, 2018Assignees: SHIRE HUMAN GENETIC THERAPIES, INC., FONDAZIONE TELETHONInventors: Muthuraman Meiyappan, Maria A. DeMatteis
-
Patent number: 9339500Abstract: The present invention relates to methods for treating, preventing or controlling vasomotor symptoms such as hot flashes comprising administering specific norepinephrine/serotonin reuptake inhibitors.Type: GrantFiled: March 4, 2009Date of Patent: May 17, 2016Assignee: INTRA-CELLULAR THERAPIES, INC.Inventor: Lawrence P. Wennogle
-
Publication number: 20150119383Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: ApplicationFiled: June 5, 2014Publication date: April 30, 2015Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
-
Patent number: 9017735Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: GrantFiled: June 3, 2010Date of Patent: April 28, 2015Assignee: Marquette UniversityInventor: Mohammadhossein Behnam Ghasemzadeh
-
Publication number: 20150098978Abstract: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke, Gerd Kobal
-
Publication number: 20150098909Abstract: A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in soluble fiber lozenge provided herein can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Feng Gao, Diane L. Gee, Shuzhong Zhuang, Phillip M. Hulan, William J. Burke, Gerd Kobal
-
Patent number: 8993558Abstract: A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof and a pharmaceutically acceptable diluent or carrier.Type: GrantFiled: October 29, 2009Date of Patent: March 31, 2015Inventor: Kenneth W. Adams
-
Patent number: 8975251Abstract: Methods and articles of manufacture for use in improving a cognitive function, utilizing a conjugate comprising a first moiety having GABA agonist activity and a second moiety having CNS activity being covalently linked to the first moiety, are disclosed. Also disclosed are methods and articles of manufacture of preventing onset or inhibiting progression of a cognitive impairment or dysfunction utilizing the disclosed conjugate.Type: GrantFiled: December 9, 2010Date of Patent: March 10, 2015Assignees: Bar-Ilan University, Ramot at Tel-Aviv University Ltd.Inventors: Yona Geffen, Kinneret Savitsky, Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Publication number: 20150031677Abstract: Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: ApplicationFiled: February 28, 2013Publication date: January 29, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Alexander M. Jacobine, Rachel D. Slack, Jennifer R. Mazzone
-
Patent number: 8940725Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: May 30, 2011Date of Patent: January 27, 2015Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20150018294Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides for methods and pharmaceutical agents to modulate the activity of Tousled-like kinase (TLK). The invention also provides for methods and pharmaceutical agents to inhibit the activity of Tousled-like kinase to provide increased sensitivity to irradiation (IR) and chemotherapeutic agents. The invention also provides for methods and pharmaceutical agents to increase the activity of Tousled-like kinase to provide increased protection against DNA damaging agents including to irradiation (IR) and chemotherapeutic agents.Type: ApplicationFiled: February 7, 2013Publication date: January 15, 2015Inventors: Arrigo DE BENEDETTI, Gulshan SUNAVALA
-
Publication number: 20140364383Abstract: Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic membrane in a flowable form and, after delivery to the tympanic membrane, becomes sufficiently viscous such that the pharmacologic agent is localized against the tympanic membrane. Such compositions can be used to prophylactically and/or therapeutically treat middle and inner ear conditions, including otitis media.Type: ApplicationFiled: May 21, 2014Publication date: December 11, 2014Applicant: Regents of the University of MinnesotaInventors: Ronald J. Sawchuk, Belinda W.Y. Cheung
-
Patent number: 8906867Abstract: The production method prepares a solid preparation by dissolving water-insoluble and/or water indissolvable alkaline active pharmaceutical ingredient in an acidifier-containing acid solution to obtain medicated acid liquid; homogeneously mixing alkalizer, adjuvants and the medicated acid liquid, and carrying out wet granulation. The alkalizer is a reagent to reduce the acidity of the mixture of the alkalizer and the medicated acid liquid relative to the acidity of the medicated acid liquid. The preparation method avoids the problems in mechanical pulverization, such as environmental pollution, great loss and serious security risks. This method is simply operated, has high safety coefficient and is convenient for industrialized production. Also disclosed is the solid preparation produced by the method. The solid preparation produced by the method has better dissolution performance than that produced by prior art, and has better or at least equivalent stability and content uniformity with prior art.Type: GrantFiled: December 28, 2010Date of Patent: December 9, 2014Assignees: Shanghai Zhongxi Pharmaceutical Company, Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.Inventors: Siji Zheng, Bo Tan
-
Publication number: 20140350000Abstract: This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided.Type: ApplicationFiled: August 13, 2014Publication date: November 27, 2014Inventors: Mark David Brennan, Timothy Lynn Ramsey
-
Publication number: 20140315897Abstract: Novel methods and compounds for treating Alzheimer's Disease are provided. In one aspect, the invention provides methods for treating Alzheimer's Disease by administering certain phenothiazine derivatives. In one embodiment, the methods include administering an effective amount of a 3-oxo-7-dialkyl-amino-phenothiazine derivative, or 3-oxo-7-dialkyl-amino-phenothiazine. In another embodiment, the invention provides methods for treating Alzheimer's Disease by administering an effective amount of a 3,7-diazetidin-1-yl-phenothiazine or a derivative thereof. In another aspect, the invention provides novel azetidinyl phenothiazine compounds.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Vishwanath Lingappa, Clarence R. Hurt
-
Publication number: 20140294994Abstract: The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and/or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.Type: ApplicationFiled: October 29, 2012Publication date: October 2, 2014Inventor: Ch-Ying Huang
-
Publication number: 20140288054Abstract: This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.Type: ApplicationFiled: October 29, 2013Publication date: September 25, 2014Applicant: SureGene, LLCInventors: Mark David Brennan, Timothy Lynn Ramsey
-
Publication number: 20140255499Abstract: A method of forming fine particles of a drug substance using a piston-gap high pressure homogeniser.Type: ApplicationFiled: October 5, 2012Publication date: September 11, 2014Inventors: Guy Vergnault, Alain Nhamias, Pascal Grenier
-
Publication number: 20140242063Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: October 10, 2013Publication date: August 28, 2014Applicant: VALEANT LABORATORIES INTERNATIONAL BERMUDAInventors: Andrew John DUFFIELD, Graham JACKSON, Steven E. FRISBEE
-
Publication number: 20140234443Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: March 10, 2014Publication date: August 21, 2014Applicant: Albany Molecular Research, Inc.Inventors: Peter R. GUZZO, David D. MANNING, William EARLEY
-
Publication number: 20140178503Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventors: Ronald C. Newbold, Chengzhi Zhang
-
Publication number: 20140079667Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.Type: ApplicationFiled: August 23, 2013Publication date: March 20, 2014Applicant: Infinity Pharmaceuticals, Inc.Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
-
Publication number: 20140047569Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: ApplicationFiled: May 3, 2012Publication date: February 13, 2014Applicant: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Publication number: 20140038949Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.Type: ApplicationFiled: February 17, 2012Publication date: February 6, 2014Applicants: IRM LLC, The Scripps Research InstituteInventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
-
Publication number: 20140030249Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: September 27, 2013Publication date: January 30, 2014Applicant: Valeant International BermudaInventors: Andrew John DUFFIELD, Graham Jackson, Steven E. Frisbee, Okponanabofa Eradiri, John CK Lai
-
Publication number: 20140024638Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, and methods for treating schizophrenia.Type: ApplicationFiled: January 17, 2012Publication date: January 23, 2014Applicant: TARGACEPT, INC.Inventors: Merouane Bencherif, Geoffrey C. Dunbar, David A. Hosford, Gregory J. Gatto, Terry Hauser, Kristen G. Jordan, Anthony Carl Segreti
-
Publication number: 20140005173Abstract: Compositions and methods for treating psychotic and neurological disorders in a subject are disclosed. The compositions and methods utilize a pharmaceutical compound that reverses or negates the effects of an NMDA receptor antagonist. The compositions and methods are effective in reducing at least catatonic features in the subject.Type: ApplicationFiled: March 20, 2012Publication date: January 2, 2014Inventor: James Conour
-
Publication number: 20130303521Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.Type: ApplicationFiled: October 26, 2012Publication date: November 14, 2013Applicant: HYDRA BIOSCIENCES, INCInventor: HYDRA BIOSCIENCES, INC
-
Publication number: 20130289004Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.Type: ApplicationFiled: October 31, 2011Publication date: October 31, 2013Applicant: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
-
Publication number: 20130289023Abstract: The preset invention relates to a new method for treating brain tumor with an antipsychotic phenothiazine derivative as a brain tumor cell inhibitor or a brain tumor stem cell inhibitor. In particular, an antipsychotic phenothiazine is accessible to brain via blood-brain barrier, which should be beneficially in treatment of brain tumor.Type: ApplicationFiled: April 30, 2013Publication date: October 31, 2013Inventors: Chi-Ying Huang, Yu-Hsin Liang, Hui-Wen Cheng
-
Publication number: 20130243886Abstract: The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.Type: ApplicationFiled: September 9, 2011Publication date: September 19, 2013Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Yanmin Hu, Anthony RM Coates
-
Publication number: 20130245004Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: ApplicationFiled: May 9, 2013Publication date: September 19, 2013Applicant: Synchroneuron Inc.Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong
-
Publication number: 20130224289Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: April 1, 2013Publication date: August 29, 2013Applicant: Depomed, Inc.Inventor: Depomed, Inc.
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Publication number: 20130184268Abstract: The invention relates to 2-(R2-thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine according to general formula I, for treating a ?-amyloidopathy or an ?-synucleinopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter. The invention also relates to a method for the diagnosis or prediagnosis of a ?-amyloidopathy or an ?-synucleopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter, or for determining the risk of a proband suffering from such an illness, the proband already having accumulated substances transported by the cerebral ABCC1 transporter.Type: ApplicationFiled: August 30, 2011Publication date: July 18, 2013Applicant: Immungenetics AGInventor: Jens Pahnke
-
Patent number: 8475813Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: November 21, 2011Date of Patent: July 2, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Publication number: 20130165427Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.Type: ApplicationFiled: August 24, 2012Publication date: June 27, 2013Applicant: HYDRA BIOSCIENCES, INC.Inventor: Jayhong A. Chong
-
Publication number: 20130157990Abstract: A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state. The method further comprises the step of administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state. The detoxification component can comprise naloxone. The method further comprises the step of administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state. The second-medication component can comprise naltrexone. The method further comprises the step of terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state.Type: ApplicationFiled: February 20, 2013Publication date: June 20, 2013Applicant: EAGLE ADVANCEMENT INSTITUTE LLCInventor: EAGLE ADVANCEMENT INSTITUTE LLC
-
Publication number: 20130150352Abstract: Novel crystalline form of perphenazine 4-aminobutyrate trimesylate and a process of producing the same are disclosed. The novel crystalline form is characterized by a unique XRPD pattern and a DSC that exhibits an endothermic peak at a relatively high temperature (e.g., higher than 209° C.). Also disclosed are a process of preparing perphenazine 4-aminobutyrate trimesylate by in situ deprotection and salification, in a single-step synthesis, and a highly pure perphenazine 4-aminobutyrate trimesylate obtained thereby. Uses of any of the described perphenazine 4-aminobutyrate trimesylate are also disclosed.Type: ApplicationFiled: February 11, 2013Publication date: June 13, 2013Applicants: Ramot at Tel-Aviv University Ltd., BioLineRX Ltd., Bar-Ilan UniversityInventors: Ramot at Tel-Aviv University Ltd., Bar-Ilan University, BioLineRX Ltd.
-
Publication number: 20130143867Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: ApplicationFiled: January 18, 2013Publication date: June 6, 2013Applicant: SYCHRONEURON INC.Inventor: SYCHRONEURON INC.
-
Patent number: 8445483Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,Type: GrantFiled: October 7, 2011Date of Patent: May 21, 2013Assignee: The Ohio State University Research FoundationInventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, John S. Gunn, Larry S. Schlesinger
-
Publication number: 20130123240Abstract: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine.Type: ApplicationFiled: January 7, 2013Publication date: May 16, 2013Applicant: Southern Research InstituteInventor: Southern Research Institute
-
Patent number: 8440821Abstract: Described is a method for the synthesis and/or purification of a high purity diaminophenothiazinium compound of the following formula: characterized by a purity of greater than 98% and less than 1% Azure B, 0.15% Azure A, 0.15% Azure C and 0.05% Methylene Violet Bernthsen (MVB), as impurities. Also described are related high purity compounds, compositions, and methods of using such compounds and compositions. The compounds and compositions are useful in the treatment of diseases caused by tau aggregation, such as Alzheimer's disease and other dementias, and infection.Type: GrantFiled: May 31, 2011Date of Patent: May 14, 2013Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20130109681Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,Type: ApplicationFiled: October 7, 2011Publication date: May 2, 2013Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, John S. Gunn, Larry S. Schlesinger
-
Patent number: 8420114Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist and at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation.Type: GrantFiled: April 15, 2009Date of Patent: April 16, 2013Assignee: Warsaw Orthopedic, Inc.Inventors: John M. Zanella, Sara Waynick
-
Publication number: 20130090329Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic signature are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the genetic signature.Type: ApplicationFiled: October 7, 2011Publication date: April 11, 2013Applicant: SUREGENE, LLCInventors: Timothy L. Ramsey, Bharat Mehrotra, Mark D. Brennan